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Abstract 13 
Chiari-like malformation/syringomyelia (CM/SM) in dogs describes a developmental 14 
disorder that can cause pain and reduced quality of life. This retrospective study aimed 15 
to report the period prevalence, clinical signs and risk factors for diagnosis of 16 
symptomatic CM/SM in the veterinary primary-care setting using a cross-sectional 17 
design. The study population included all dogs within the VetCompass Programme 18 
(01/09/2009-13/06/2014).  19 
Overall, the period prevalence of symptomatic CM/SM was 0.05% (95% confidence 20 
interval (CI) 0.04% to 0.06%) for all breeds. The period prevalence in the Cavalier King 21 
Charles Spaniel was 1.6% (95% CI 1.2-2.06). Other breeds at increased odds included 22 
the King Charles Spaniel, Affenpinscher, Chihuahua and Pomeranian. Insured dogs had 23 
4.6 times the odds (95% CI 2.95-7.17) of having a diagnosis of CM/SM compared with 24 
uninsured dogs. Pain was the most common associated clinical sign (67 dogs, 72%). 25 
Analgesics were prescribed to 72 (77.4%) of the symptomatic dogs.  26 
Despite its low overall period prevalence, the high proportion of affected dogs 27 
identified with chronic pain suggests a significant welfare issue. Financial implications 28 
could impede the diagnostic process and lead to under-estimation of the true 29 
prevalence.  This study may help to inform clinicians about the clinical relevance and 30 
the need for improved awareness of clinical signs, particularly in high-risk breeds, to 31 
optimise the management of CM/SM in primary-care practice.  32 
Keywords 33 
Epidemiology; Chiari-like malformation; syringomyelia; prevalence; dog; breed; 34 
electronic patient record; primary-care; veterinary  35 
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Introduction 36 
Canine Chiari-like malformation and syringomyelia are two closely linked conditions 37 
that are often recorded as a single entity (Driver and others 2013). Canine Chiari-like 38 
malformation (CM) and syringomyelia (SM) may occur independently or concurrently 39 
within affected individuals and may manifest symptomatically or asymptomatically 40 
(Gamache and Ducker 1990; Parker and others 2011; Plessas and others 2012). CM/SM 41 
may be diagnosed as a single entity in primary-care practice (Summers and others 2015) 42 
and has been associated with an array of neurological signs that may severely 43 
compromise quality of life (Rutherford and others 2012). 44 
Miniaturisation and brachycephaly are reported risk factors for CM (Schmidt and others 45 
2011; Marino and others 2012; Driver and others 2013). CM cases have been reported 46 
in many dog breeds with these attributes including the Cavalier King Charles Spaniel 47 
(CKCS) (Dewey and others 2005; Rusbridge 2007; Marino and others 2012; Harcourt-48 
Brown and others 2015), French bulldog, Griffon Bruxellois, Chihuahua, Pomeranian, 49 
Maltese terrier, Pug and Yorkshire terrier (Marino and others 2012). Prevalence 50 
estimates for CM (with or without SM) in the CKCS range from 92-100% (Couturier 51 
and others 2008; Cerda-Gonzalez and others 2009). A study of CKCS using magnetic 52 
resonance imaging (MRI) screening in the UK and the Netherlands, reported that 25% 53 
of CKCS up to the age of 12 months old were reported to have asymptomatic SM, and 54 
that 70% of the dogs have developed SM (symptomatic or asymptomatic) by the age of 55 
6 years (Parker and others 2011). However, there are currently few data available on 56 
the occurrence of symptomatic CM/SM in dogs presenting to primary-care veterinary 57 
practices across all breeds known to be affected.  58 
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The most common signs reported for CM/SM are various manifestations of pain, 59 
phantom scratching and neurological signs (notably scoliosis, thoracic limb weakness 60 
and pelvic limb ataxia) (Rusbridge and others 2006). It is considered that dogs affected 61 
by CM/SM experience chronic neuropathic pain which increases anxiety levels and 62 
fear-associated behaviour and decreases the quality of life of affected individuals 63 
(Rutherford and others 2012). However, no studies to date have described the clinical 64 
signs reported for CM/SM cases in dogs presenting in primary-care practice. 65 
The progressive nature of the disease, its frequent severity (Plessas and others 2012) 66 
and the high financial burden associated with its diagnosis and treatment can have 67 
substantial emotional and economic impact on owners of CM/SM dogs (Shepherd 68 
2008; Franklin and others 2013). Reaching a definitive CM/SM diagnosis can be 69 
challenging in primary-care practice. Typical clinical signs overlap with several other 70 
disorders and lack specificity, whilst access to MRI imaging facilities may be limited 71 
and prohibitively expensive. Conversely, the high proportion of dogs that have CM/SM 72 
changes evident on MRI, but appear clinically asymptomatic, frustrates attempts to 73 
define the prevalence of clinically affected cases (Rusbridge and others 2006).  74 
This study aimed to (i) report the period prevalence of symptomatic CM/SM diagnosed 75 
in primary-care practice in England across all breeds and in CKCS, (ii) describe 76 
associated risk factors (including breed) (iii) report the clinical signs shown and 77 
treatments prescribed, and (iv) provide information that could lead to improved welfare, 78 
emotional and economic impact.   79 
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Materials and Methods 80 
The RVC Ethics and Welfare Committee gave ethical approval for this study (ref: URN 81 
2010 1067i). The VetCompass Programme collects primary-care veterinary clinical 82 
data (signalment, clinical examination, diagnosis and treatment) from practices 83 
throughout the UK (O’Neill and others 2014; VetCompass 2015).  84 
This study interrogated clinical data on all dogs shared with VetCompass from 85 
01/09/2009 to 13/06/2014 which, at that time, covered veterinary practices located 86 
across central and southern England (VetCompass 2015). Information collected 87 
included patient demographic (species, breed, date of birth, gender, neuter status, 88 
colour, insurance status and bodyweight) and clinical information (free-form text 89 
clinical notes, VeNom summary diagnosis terms and treatment, with relevant dates) 90 
data fields (VeNom Coding Group 2014). Potential CM/SM cases were identified from 91 
the free-text and VeNom Code fields using key-search terms (including 92 
“SM”/”Chiar”/”Syrin”) and were manually reviewed for case inclusion by the first 93 
author of the manuscript (veterinary surgeon).  94 
Inclusion as a case required a final diagnosis of CM/SM (or synonym) documented in 95 
the veterinary clinical records of a clinically affected dog. The case definition accepted 96 
a diagnostic process based on anamnesis and clinical examination and did not mandate 97 
any need for MRI. Cases of CM/SM diagnosed using MRI that were asymptomatic or 98 
that had signs compatible with CM/SM but that were attributed to alternative concurrent 99 
clinical conditions (such as intervertebral disc disease or other neurological problems, 100 
dermatological problems, orthopaedic problems) were excluded. Information about 101 
clinical signs, treatment received and responsiveness and, as applicable, death, were 102 
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recorded. All these features were used for descriptive statistics for welfare, emotional 103 
and economic impact. 104 
All dogs in the study population that were not defined as CM/SM cases were included 105 
as non-cases for risk factor analysis to investigate the odds of having a diagnosis of 106 
CM/SM. Breed, sex, age and insurance status were included in the analysis. Crossbred 107 
was considered as control. Insurance status described whether the dog was insured at 108 
any point during the study period. Age was defined as the age at first diagnosis for 109 
incident cases, or the age at the centre point between the first and final record for the 110 
non-cases. No age at diagnosis value was included for pre-existing cases (and so the 111 
age of these animals was treated as a missing value). Age was categorised into the four 112 
groups used by the British Veterinary Association and the Kennel Club CM/SM 113 
Scheme (< 1 year, between 1 and 3 years old, between > 3 and 5 years old and > 5 114 
years) (The Kennel Club 2015a). For CKCS, an additional analysis was carried out 115 
within the study population of all CKCS’s presenting during the study period and 116 
included the above risk factors as well as coat colour (The Kennel Club 2015b). 117 
Considering the expected low prevalence of CM/SM in the general canine population 118 
of England, a ‘period prevalence’ was calculated, which was used to investigate the 119 
prevalence of symptomatic CM/SM in dogs diagnosed prior to the study period, as well 120 
as those who developed the disease during the period (incident cases). Incident cases 121 
were dogs that were first diagnosed with CM/SM during the study period whilst pre-122 
existing cases were defined as dogs first diagnosed prior to the study period.  123 
For incident CM/SM cases, additional information was extracted to compare treatments 124 
undertaken and number of visits to assist with estimation of financial and welfare 125 
impact: we also noted whether MRI was used during diagnosis, date of diagnosis, 126 
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treatment methods, veterinary surgeon prescribing the treatment (i.e. specialist or 127 
primary-care veterinary surgeon), referral for specialist care and total number of 128 
veterinary visits related to CM/SM during the study period.  These data were only 129 
collected from incident CM/SM cases because complete clinical records may not have 130 
been available in VetCompass for pre-existing cases diagnosed prior to the study 131 
period.  132 
Data were exported from the VetCompass database to a spreadsheet (Microsoft Excel 133 
2013 for Windows) for cleaning and formatting. Online software (QuickCalcs, 134 
GraphPad Software) was used to calculate 95% confidence intervals (CIs) for 135 
prevalence estimates, via a modified Wald method. Data analysis used statistical 136 
software (IBM SPSS 21). Demographic variables were explored and described using 137 
number and percentage for categorical data and medians (interquartile range (IQR), 138 
range) for continuous data. Association between referred cases or those only seen in 139 
primary-care practice treatment options, number of drugs used and total number of 140 
veterinary visits were evaluated using the chi-squared or Mann Whitney U tests, as 141 
appropriate (Field 2013).  142 
Risk factor analysis evaluated associations between demographic variables and the 143 
odds of obtaining a diagnosis of CM/SM. Univariate binary logistic regression analysis 144 
was conducted and factors with a significance level of p ≤ 0.2 were added into 145 
multivariable logistic regression modelling for further assessment. Model building used 146 
manual backwards elimination and the best-fit model was assessed using a likelihood 147 
ratio test (Dohoo 2009). Results were considered statistically significant if p < 0.05.  148 
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Results 149 
The study population included 187,326 dogs with records on the VetCompass database 150 
from 01/09/2009 to 13/06/2014 (Figure 1). There were 89,339 females (47.5%), 74,624 151 
dogs were neutered (39.8%), 40,209 were crossbred (54.2%) and 48,119 dogs (25.7%) 152 
were insured.  153 
Ninety-three symptomatic CM/SM cases met the case definition, giving a period 154 
prevalence overall of 0.05% (95% CI, 0.04%-0.06%). Of these cases, 34 dogs (36.6%) 155 
were female, 60 dogs (64.5%) were neutered and 63 dogs (67.7%) were insured.  156 
The most commonly affected breed overall was the CKCS, accounting for 65 (69.9%) 157 
of the case dogs (Table 1). Other breeds affected included the King Charles Spaniel (16 158 
dogs, 17.2%), crossbred (3 dogs, 3.2%), Chihuahua, Yorkshire terrier (two dogs each, 159 
2.2 %,) and the Pug, Affenpinscher, Jack Russell terrier, Pomeranian and Shih Tzu (one 160 
dog each, 1.1%). Of the three recorded crossbred CM/SM cases, two were recorded as 161 
being partly CKCS. 162 
In the 93 cases, the most common sign reported for CM/SM was pain (67 dogs, 72%) 163 
(Figure 2). The most common manifestations were phantom scratching (36 dogs, 164 
38.7%), spontaneous yelping (27 dogs, 29%), neck pain on palpation (16 dogs, 17.2%) 165 
and provoked yelping, e.g., vocalisation when picked up or touched (15 dogs, 16.1%). 166 
Treatment data were available for 89 of the 93 affected dogs. Seventy two dogs (77.4%) 167 
received one or more drugs for treatment of CM/SM, and 17 dogs (20.4%) were un-168 
medicated. Gabapentin, non-steroidal anti-inflammatory drugs (NSAIDs) and 169 
corticosteroids were the most commonly prescribed treatments for CM/SM, 170 
administered to 48 dogs (67%), 47 dogs (65%) and 23 dogs (32%), respectively (Figure 171 
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3). Of the 17 unmedicated dogs, six were reported to have pain and six were reported 172 
to show only scratching behaviour (35.2% each). Of the 72 medicated dogs, 64 (88.8%) 173 
were reported to show either a partial or a full response to medication while the 174 
remaining nine dogs (12.5%) were reported to have not improved after treatment. Two 175 
dogs (2.1% of cases) underwent surgery for CM/SM but the outcomes of surgery were 176 
not recorded. During the study period, 23 of the 93 case dogs overall were 177 
euthanised/died (24.8%). Of the 93 case dogs, nine (9.8%) died or were euthanised as 178 
a result of CM/SM. 179 
Risk factor analysis of diagnosis of CM/SM across all breeds: 180 
Univariable risk factor analysis identified breed, age and insurance as risk factors for 181 
symptomatic CM/SM (Table 2). 182 
Multivariable analysis identified three risk factors associated with CM/SM: breed, age 183 
and insurance. The CKCS (OR 175, 95% CI 55.14-560.81, p<0.001), King Charles 184 
Spaniel (OR 226.80, 95% CI 65.82-781.45, p<0.001), Affenpinscher (OR 109, 95% CI 185 
5.93-552.59, p<0.001), Chihuahua (OR 7.4, 95% CI 1.24-44.71, p=0.028) and 186 
Pomeranian (OR 14.8, 95% CI 1.54-143.17, p=0.02) breeds all had increased odds of 187 
diagnosis compared with crossbreds. Dogs aged over five years had 2.7 (95% CI 1.02-188 
7.41, p=0.045) times the odds of diagnosis of symptomatic CM/SM compared with 189 
dogs of less than one year of age. Insured dogs had 4.6 (95% CI 2.95-7.17, p<0.001) 190 
times the odds of CM/SM compared with uninsured dogs (Table 2).  191 
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Incident cases and comparison between referred and non-referred cases 192 
Incident cases accounted for 48 dogs (51.6%); the remaining 45 dogs (48.4%) had pre-193 
existing records of CM/SM. The median age at diagnosis for the incident cases was 194 
4.25 years (IQR: 2-4.25 years, range 0.21-12.07 years). Of the 48 incident CM/SM 195 
cases, MRI had contributed to the diagnostic decision in 36 dogs (75%) (Table 3) while 196 
12 dogs (25%) were diagnosed using only anamnesis, physical exam and radiography. 197 
In three of these twelve dogs, radiography was performed to exclude possible 198 
orthopaedic disease and discospodylitis. For the incident cases, the number of 199 
veterinary visits due to CM/SM during the study period ranged from 1 to 15, with 12 200 
dogs (25%) visiting their primary-care practice on more than seven occasions due to 201 
this disorder.  202 
Referred (n=36) and non-referred dogs (n=12) were compared for their first line drug 203 
treatment, drugs prescribed and number of visits to the primary-care practice. No 204 
significant difference was identified for gabapentin (p=0.082) or NSAIDs (p=0.253) 205 
as first drug used between dogs referred and dogs seen only by the primary-care 206 
veterinary surgeon. However, the total number of drugs prescribed per dog during the 207 
treatment period was significantly higher in referred dogs (median of 2 drugs, range 1-208 
6 drugs) than those not referred (median 1 drug, range 1-2 drugs), (p=0.009). Referred 209 
dogs (median 5 visits, range 1-15 visits) also had significantly more veterinary visits to 210 
the primary-care practice for CM/SM compared to dogs that were never referred 211 
(median 3 visits, 1-10)  (p=0.005). 212 
CM/SM diagnosed in the CKCS: 213 
The study included 4,046 CKCSs (2.2% of the overall study population), of which 214 
1,847 (45.7%) were female, 1,910 (47.2%) were neutered and 1,433 (35.4%) were 215 
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insured. The coat colour distribution included 1,894 (47%) Blenheim, 559 (13.9%) 216 
ruby, 156 (3.9%) black and tan and 1,420 (35.2%) tricolour. 217 
There were 65 CM/SM cases diagnosed in the CKCS breed, giving a period prevalence 218 
of symptomatic CM/SM of 1.6% (95% CI 1.2%-2.06%). Of these overall cases, there 219 
were 29 (44.6%) females, 42 (64.6%) neutered and 44 (67.7%) insured CKCSs. Among 220 
the cases, 34 (52.3%) were Blenheim, 8 (12.3%) ruby, 3 (4.6%) black and tan, and 20 221 
(30.8%) tricolour. During the study period, 11 of the 65 symptomatic CKCS were 222 
euthanized/died (27.7%). Nine of symptomatic CKCS (10.8%) died directly as a result 223 
of CM/SM.  224 
Univariable risk factor identified that insured dogs had 3.9 times greater odds of 225 
diagnosis (OR 3.91 95% CI 2.31-6.60, p<0.001) (Table 4). There were no significant 226 
associations of sex or coat colour with the diagnosis of symptomatic CM/SM in CKCS. 227 
Age group (p=0.195), and insurance status (p<0.001) were included in the multivariable 228 
risk factor analysis. Only insurance was significantly associated with an increased odds 229 
of symptomatic CM/SM in CKCS (OR 3.88 95% CI 2.29-6.55, p<0.001).  230 
Of the CKCS considered as cases, 29 (44.6%) were incident cases. that showed a 231 
median age for diagnosis of 4.5 years (IQR 2.94-6.78 years, range 1.6-11.5 years). MRI 232 
was used in the diagnosis of 20 (69%) CM/SM cases while nine (31%) diagnoses did 233 
not include MRI.  234 
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Discussion  235 
This is the largest epidemiological study to explore symptomatic CM/SM in the general 236 
population of practice-attending dogs in England. Analysis of primary-care veterinary 237 
data is critically important to assist our understanding of diagnosis, management and 238 
clinical impact of CM/SM in the overall canine population and in specific breeds such 239 
as the CKCS.  240 
Prevalence of CM/SM in dogs 241 
In the current study, the period prevalence of symptomatic CM/SM reported for all dogs 242 
was low in comparison with the most common disorders reported in primary-care 243 
practice in dogs (O'Neill and others 2014) where otitis externa, periodontal diseases 244 
and anal sac impaction had prevalences of 10.2%, 9.3% and 7.1%, respectively. The 245 
large range of breeds included in the study population could explain these figures, as 246 
many breeds are not at risk (non-brachycephalic or large breed) of suffering CM/SM.  247 
Underestimation of the true prevalence 248 
Diagnosis of CM/SM generally requires an MRI (Rusbridge and others 2006). 249 
However, this is a major limitation in primary-care practice. A significant proportion 250 
of dogs in this study were excluded because a clinical diagnosis was not made despite 251 
possible signs of CM/SM being present and because clinical signs could be confounded 252 
with other diagnosed diseases (Figure 1).  This is an important source of 253 
underestimation of the true prevalence. It is also a concern as many dogs will not reach 254 
a final diagnosis and therefore will not be appropriately treated. This leads to a decrease 255 
in welfare of these patients. Some dogs have been diagnosed without MRI and therefore 256 
false positives may have been included. Nevertheless, the data provided in this paper 257 
reflects how veterinary primary-care practitioners identify and approach these cases, 258 
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sometimes without the possibility of reaching a full confirmation with diagnostic 259 
imaging.  260 
Owner awareness of normal and abnormal behaviour is also important to detect when 261 
their dogs are in pain. The most common clinical signs shown by dogs affected with 262 
CM/SM in the current study are similar to previous reports (Rusbridge 2007), although 263 
a higher proportion of symptomatic animals were reported to show pain in the current 264 
study (72% compared to 35% in previous investigations) (Rusbridge and others 2007). 265 
Breakdown of the most common manifestations of pain showed a wide range of non-266 
specific presentations. Further research is needed to elucidate the difference between 267 
scratching and pain; the most recent research suggests they are underpinned by separate 268 
pathways (Sun and Chen 2007; Rusbridge and Jeffery 2008; Sun and others 2009). 269 
However, there is no evidence that scratching is less uncomfortable than pain for these 270 
patients. Veterinary practitioners may miss the different manifestations of pain 271 
reflected in this paper and described in the literature (Rusbridge and others 2006) if 272 
owners do not report this signs as abnormal or disturbing. Therefore, knowledge of the 273 
spectrum of behavioural and pain-related clinical signs shown by CM/SM cases could 274 
improve diagnosis by increasing awareness in primary-care clinicians of the importance 275 
of targeted questioning and history-taking of owners who may even be unaware that 276 
these factors are clinically relevant. 277 
The increased diagnosis level recorded in insured animals suggests that financial and 278 
other constraints on diagnostic procedures may have allowed the true prevalence of 279 
CM/SM in the overall population to be under-estimated.  Lack of insurance could 280 
potentially lead to fewer dogs being given a final diagnosis of CM/SM especially if 281 
dogs other than CKCS show clinical signs associated with this disease complex, where 282 
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CM/SM will be in a lower position on (or even absent from) the differential diagnosis 283 
list  and an MRI may be needed to confirm its presence. 284 
Veterinary clinical data are mainly recorded for clinical use and are not specifically 285 
recorded for research purposes. So, a combination of these factors implies that figures 286 
reported here are likely to be underestimates of prevalence. 287 
CM/SM diagnosed in the CKCS 288 
The current study identified the CKCS as a predisposed breed (prevalence of CM/SM: 289 
1.6%) in agreement with other studies (Marino and others 2012;  Harcourt-Brown and 290 
others 2015). The period prevalence of symptomatic CM/SM in CKCS aligns with the 291 
results of Summers and others (2015), who reported symptomatic CM/SM in 1.7% of 292 
CKCS in primary-care practice. Although a recent study of CKCS reported 15% 293 
prevalence for symptomatic CM/SM in Denmark (Thofner and others 2015), the age 294 
range it focussed on was restricted to dogs aged over six years whereas the current study 295 
included dogs of all ages. However, responder bias in the Danish study could have 296 
resulted from some over-reporting of the condition because respondents were asked to 297 
volunteer their time to fill-in the questionnaire and it can be assumed that owners with 298 
experience and awareness of CM/SM would be more inclined to participate in this kind 299 
of study (Thofner and others 2015). Other reports on CM/SM prevalence originate 300 
mainly from investigations relying, for definitive diagnosis, on MRI (Parker and others 301 
2011; Thofner and others 2015) among all cases (symptomatic and asymptomatic) 302 
rather than records of clinically affected animals from primary-care practice which are 303 
the dogs that have compromised welfare.  This may help to account for some of the 304 
apparent discrepancies because these studies often included asymptomatic animals as 305 
cases. 306 
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It has been reported that young dogs with asymptomatic SM develop clinical signs later 307 
in life (Ives and others 2015), thus increasing the prevalence of dogs with clinical signs 308 
in older CKCS. This is in line with our findings, as dogs over five years old had 309 
increased odds of having a diagnosis of symptomatic CM/SM in all breeds.  310 
The literature reported CM/SM to be more common in Blenheim and ruby CKCSs, 311 
which are recessive coat colours (Rusbridge and Knowler 2004). Nevertheless, the 312 
current study failed to identify a significant association between colour coat and 313 
symptomatic CM/SM diagnosis. Similarly, age did not statistically affect symptomatic 314 
diagnosis in the CKCS, whereas in other studies there was a higher prevalence in dogs 315 
older than 3 years of age (Rusbridge 2007; Parker and others 2011). Results of the risk 316 
factor analysis in CKCS could be explained by lack of statistical power due to a small 317 
sample size, suggesting that even larger studies are needed to more confidently identify 318 
risk factors associated with the diagnosis of symptomatic CM/SM in individual breeds. 319 
Although KCS and CKCS are recognised as distinct breeds by the Kennel Club (The 320 
Kennel club, 2015b), breed classification in the current study relied on the recorded 321 
breed information provided by the owners and veterinary teams as recorded in the 322 
clinical notes. Because these two breeds are phenotypically similar, it is possible that 323 
some recorded KCS may actually have been CKCS and vice versa. 324 
Other breeds affected 325 
The current results from demographic analysis of cases are generally consistent with 326 
the affected breeds and age of onset previously reported (Rusbridge and others 2007; 327 
Parker and others 2011; Harcourt-Brown and others 2015). The main breeds identified 328 
as affected by symptomatic CM/SM in the current study align with those reported in 329 
the literature with brachycephalic and miniature breeds being predisposed (Thofner and 330 
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others 2015). Risk factor analysis revealed that CKCS, King Charles Spaniel, 331 
Pomeranian, Chihuahua and Affenpinscher had increased odds of diagnosis of 332 
symptomatic CM/SM compared with crossbreds. Jack Russell Terriers and Yorkshire 333 
Terriers, although not identified at increased risk in this study, were also diagnosed. 334 
These findings suggest that some breeds other than the CKCS have similar 335 
morphological characteristics associated with CM/SM (Marino and others 2012; Cerda-336 
Gonzalez and others 2015). However, Griffon Bruxellois was underrepresented in the 337 
current study despite having high CM/SM incidence in other studies (Rusbridge and 338 
others 2009; Marino and others 2012). Two of the three crossbreds in the study were 339 
partly CKCS, indicating that despite introduction of new genetic material from 340 
crossing, causative factors of CM/SM are likely to be inherited (Rusbridge and Knowler 341 
2003; Knowler and others 2016). This information helps veterinary practitioners to 342 
consider CM/SM as a differential diagnosis in these breeds when normally it would not 343 
have been considered as a possible cause of the clinical signs observed. 344 
Management of CM/SM 345 
This study identified that gabapentin and NSAIDs were the most commonly used 346 
treatments for CM/SM. These findings are consistent with published advice that 347 
gabapentin is the first line treatment for neuropathic pain with the addition of NSAIDs 348 
if there is an inflammatory component (Grubb 2010). Gabapentin and NSAIDs have 349 
been recommended specifically to treat neuropathic pain of CM/SM origin (Rusbridge 350 
and others 2006), although the efficacy of NSAIDs in controlling pain of CM/SM origin 351 
is currently unclear (Rusbridge and Jeffery 2008). The current study failed to identify 352 
any statistically significant difference in the usage of analgesics between referred and 353 
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non-referred dogs. These results suggest that primary-care veterinary practitioners are 354 
closely mirroring the CM/SM treatment protocols of referral practitioners. 355 
Welfare, emotional and economical features 356 
Apart from treatment regimes, management practices differed between dogs that were 357 
referred and those that attended only primary-care practice. Referred dogs had more 358 
veterinary visits and more drugs prescribed compared with non-referred, possibly 359 
because of higher clinical severity in referred dogs. Insured animals had 4.6 times the 360 
odds of a CM/SM diagnosis, possibly because of fewer financial restrictions on the use 361 
of MRI for diagnosis as well as more frequent veterinary visits and owners arguably 362 
having stronger bonds with their dogs (Egenvall and others 2009; Stephens and others 363 
2014). These findings underline the impact of household finance and owner dedication 364 
on the diagnosis of CM/SM. 365 
The welfare impact of any condition in a population can be considered in terms of the 366 
proportion of individuals affected, but also in terms of the severity and the duration of 367 
the challenge experienced by individuals (Collins and others, 2011; Buckland and 368 
others, 2014). The mortality results for cases indicated that, although some animals 369 
were euthanized on welfare grounds because of CM/SM, a large proportion lived for 370 
years with the condition. The percentage of symptomatic dogs in this study that were 371 
not receiving any treatment (18.3%) is an interesting finding. Due to the progressive 372 
nature of the CM/SM (Plessas and others 2012), it is important that the condition is 373 
appropriately managed to maintain the quality of life of affected individuals. Owners 374 
of untreated but symptomatic CM/SM dogs may have attributed the clinical signs seen 375 
(e.g., phantom scratching) to normal behaviour for the individual or breed and judged 376 
it as non-distressing to their pet. Equally, owners may become habituated to 377 
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manifestations of pain in their dogs. Thus, educating owners about the likely cause and 378 
possible impact on dog welfare of such clinical signs is important to improve diagnosis, 379 
especially if MRI is not an option, and ensure effective treatment of any unpleasant 380 
sensations (Rutherford and others 2012). All these factors highlight the welfare impact 381 
of this complex disorder. 382 
There were some limitations to the current study. Referral institutions normally treat 383 
selected diseases associated with more specialised care, representing a source of bias 384 
when these data are used for generalizable prevalence estimation (Bartlett and others 385 
2010). On the other hand, epidemiologic data at primary-care veterinary clinics may be 386 
unrepresentative by the absence of more severe disease phenotypes or conditions that 387 
are diagnosed more commonly at referral clinics (Bartlett and others 2010). However, 388 
in most cases, the diagnosis made at the referral centres will still appear in the primary-389 
care records. Breed predisposition leads to the risk of confirmatory bias and dogs 390 
classified in this study as a CM/SM case could have been free of CM/SM changes in 391 
the MRI. 392 
In conclusion, this study identified that symptomatic CM/SM appears to be a painful 393 
disease, with varied clinical manifestations, that persists over time with a low rate of 394 
mortality but often demands prolonged poly-pharmacy. A low apparent prevalence of 395 
0.05% symptomatic CM/SM in the overall first opinion population was identified, with 396 
many potential reasons of underestimation of the true prevalence. However, a 397 
substantially higher apparent prevalence of 1.6% emerged in CKCSs, which in addition 398 
to the data showing 72% of affected dogs showed signs of pain, suggests that CM/SM 399 
should be considered a disorder of major welfare impact on this breed. Financial 400 
limitations complicate a final diagnosis, such that affected dogs may remain untreated. 401 
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These results should help clinicians to improve the diagnosis and case management of 402 
CM/SM in dogs and may inform control strategies for the disorder in dogs overall and 403 
especially in predisposed breeds 404 
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Table 1. Period prevalence of symptomatic CM/SM reported in primary-care veterinary practice in individual breeds of dogs. N/A: not applicable 
 
  
 
 
  
Breed 
Total number  
of dogs 
Number of diagnosed dogs 
CM/SM cases 
Prevalence 
Number of cases that 
included MRI 
diagnosis 
Cavalier King Charles 
Spaniel 
4,046 65 1.6 % (95% CI 1.20-2.06) 36  
King Charles Spaniel 871 16 1.84% (95% CI 1.09-3.04) 12  
Affenpinscher 235 1 0.4% (95% CI 0.01-2.62) 1  
Pomeranian 934 1 0.1% (95% CI 0.01-0.67) 0  
Pug 1,726 1 0.06% (95% CI 0.01-0.36) 1 
Chihuahua 4,072 2 0.05%(95% CI 0.01-0.19) 1  
Yorkshire Terrier 6,299 2 0.03%(95% CI 0.01-0.12) 2 
Shih Tzu 3,706 1 0.03% (95% CI 0.01-0.17) N/A 
Jack Russell Terrier 12,024 1 0.01% (95% CI <0.01-0.06) 1 
Cross Breeds 40,208 3 N/A 3 
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Table 2. Risk factor analysis for diagnosis of CM/SM in all breeds of dogs. CKCS: Cavalier King 
Charles Spaniel; KCS: King Charles Spaniel; * indicates a statistically significant result (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Univariable Binary Logistic Regression Analysis of All Breeds 
Variable Categories OR 95% CI p value 
Sex 
Female (Base) 
Male 
1 
1.58 
 
1.04-2.42 
 
0.324 
Insurance 
Status 
Not insured (Base) 
Insured 
1 
6.08 
 
3.93 – 9.39 
 
<0.001* 
Breed 
Cross breed (Base) 
Affenpinscher 
Chihuahua 
Pomeranian 
Pug 
Shih Tzu 
CKCS 
KCS 
Jack Russell Terrier 
Yorkshire Terrier 
Remaining pure breed 
1 
57.28 
6.55 
14.37 
7.72 
3.65 
218.82 
250.71 
1.18 
4.24 
0 
 
5.93-552.59 
1.10-39.42 
1.49-138.21 
0.80-74.72 
0.37-34.78 
68.74-696.52 
72.94-862.29 
0.11-10.71 
0.71-25.47 
0-5.57E+096 
<0.001* 
<0.001* 
0.039* 
0.021* 
0.076 
0.266 
<0.001* 
<0.001* 
0.925 
0.113 
0.922 
Age group 
<1 year old (Base) 
1 year to 3 years 
>3 years to 5 years 
>5 years 
1 
2.11 
4.44 
2.93 
 
0.81-5.52 
1.72-11.17 
1.12-7.75 
0.002* 
0.121 
0.002* 
0.027* 
Multivariable Binary Logistic Regression Analysis of All Breeds 
 
Variable Categories OR 95% CI 
 
p value 
 
Insurance 
Status 
Not Insured (Base) 
Insured 
1 
4.63 
 
2.95-7.174 
 
<0.001* 
Breed 
Cross breed (Base) 
Affenpinscher 
Chihuahua 
Pomeranian 
Pug 
Shih Tzu 
CKCS 
KCS 
Jack Russell Terrier 
Yorkshire Terrier 
Remaining pure breed 
1 
109.70 
7.46 
14.86 
7.99 
3.72 
175.86 
226.80 
1.17 
4.49 
0 
 
11.25-1069.14 
1.24-44.71 
1.54-143.17 
0.83-76.93 
0.38-35.85 
55.14-560.81 
65.82-781.45 
0.12-11.30 
0.75-26.91 
0-7.55E+092 
<0.001* 
<0.001* 
0.028* 
0.020* 
0.072 
0.255 
<0.001* 
<0.001* 
0.889 
0.100 
0.917 
Age group 
< 1 year old (Base) 
1 year to 3 years 
> 3 years to 5 years 
> 5 years 
1 
0.88 
1.43 
2.71 
 
0.51-1.54 
0.84-2.39 
1.02-7.41 
0.060 
0.674 
0.184 
0.045* 
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Table 3.  Descriptive information used in the diagnosis of CM/SM reflecting welfare of dogs, emotional and economic owners’ impact (results are based only on dogs where 
appropriate information was available).   
 
Descriptor N of dogs % 
MRI used in diagnosis- referred to specialists (incident cases only) 36/48 75 
In pain 67/93 72 
On treatment 72/89 80.8 
Treated with more than 3 drugs (range= 1-6 drugs) 13/72 18 
Non-responders at all to treatment 9/72 10 
Un-treated with pain 6/58 10.3 
More than 7 visits due to CM/SM (incident cases only, range= 1-15 visits) 12/47 25.5 
Died/euthanized due to CM/SM 9/93 9.8 
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Table 4. Risk factor analysis for diagnosis of CM/SM in Cavalier King Charles Spaniels (CKCS), * indicates statistically significant result (p<0.05). 
 
Univariable Binary Logistic Regression Analysis of CKCS 
Variable Categories OR 95% CI p value 
Sex 
Female(Base) 
Male 
1 
1.04 
 
0.641-1.717 
 
0.850 
Insurance Status 
Not Insured (Base) 
Insured 
1 
3.91 
 
2.31-6.60 
 
<0.001* 
Colour coat 
Blenheim (Base) 
Ruby 
Black and Tan 
Tricolour 
1 
0.79 
1.07 
0.78 
 
0.36-1.72 
0.32-3.53 
0.44-1.36 
0.807 
0.561 
0.908 
0.385 
Age group 
<1 year old(Base) 
1 year to 3 years 
>3 years to 5 years 
>5 years 
1 
2.86 
0.84 
1.21 
 
0.94-8.64 
0.44-1.61 
0.65-2.24 
0.156 
0.062 
0.603 
0.539 
Multivariable Binary Logistic Regression Analysis of CKCS 
 
Variable Categories OR 95% CI p value 
Insurance Status 
Not Insured (Base) 
Insured 
1 
3.88 
 
2.29-6.55 
 
<0.001* 
Age group 
<1 year old(Base) 
1 year to 3 years 
>3 years to 5 years 
>5 years 
1 
2.67 
0.83 
1.19 
 
0.87-8.13 
0.43-1.59 
0.64-2.21 
0.195 
0.084 
0.575 
0.578 
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Figure 1. Flow diagram of dogs entered on VetCompass projecting forward to CM/SM 
case group. Note that there were dogs excluded in the case definition. There were 79 dogs for 
which CM/SM was within the differential diagnosis of the veterinary surgeon and were 
considered cases but were excluded because of insufficient evidence. Forty of these occurred 
with other painful diseases (IVDD, meningitis) or scratching (otitis and dermatological 
diseases). Six dogs with CM/SM confirmed by MRI were excluded because they displayed 
signs of pain compatible with intervertebral disc disease seen on MRI. 
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Figure 2. Clinical signs reported in dogs diagnosed with symptomatic CM/SM in 
primary-care veterinary practice. Signs are organised by main types of clinical signs: 
scratching (blue), pain (red), neurological signs (green), behavioural changes (yellow) and 
non-specific (black). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
Figure 3. Proportion of drugs prescribed to symptomatic CM/SM cases diagnosed in 
dogs attending primary-care veterinary practice in England. Dogs might receive more 
than one treatment. 
 
 
